Actively Recruiting

Age: 16Years +
All Genders
ID06610201

Velora Discover: A Prospective, Screening Study of Bleeding and Treatment in Participants With Von Willebrand Disease

Led by Hemab ApS · Updated on 2026-04-21

200

Participants Needed

17

Research Sites

N/A

Total Duration

On this page

AI-Summary

What this Trial Is About

Researchers are studying people with Von Willebrand Disease (VWD), focusing on how often bleeding events happen, their impact on quality of life, and the social and clinical effects of bleeds. This screening study gathers baseline data on bleeding and treatment rates in participants with VWD, mainly Type 1, but may include Types 2 and 3 with sponsor approval. The findings will help compare outcomes in future clinical studies like Velora Pioneer. The study involves screening and a baseline check, followed by an observation period of about 4 months during which participants will have telemedicine check-ins every two weeks. These check-ins monitor bleeding events and treatment use through a bleed diary. Participants can opt to extend this observation period up to 12 months if they wish. Participants will provide information about their bleeding events and treatments during the study. Researchers will assess bleeding rates, hospital stays, and quality of life using questionnaires and clinical evaluations. Outcomes measured include annual bleeding rates, treatment use, iron status, and bleeding severity scores. The study concludes with data collection over the observation period, helping to understand the experience of people with VWD over time.

CONDITIONS

Brief Title

A Study of Bleeding and Treatment in Participants With Von Willebrand Disease

Who Can Participate

Age: 16Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Ability to provide informed consent according to regulations
  • Willingness and ability to comply with study procedures
  • Age between 16 and under 70 years at screening
  • Weight between 50 and 120 kg (±10%) and BMI less than 38.5 kg/m²
  • Diagnosed with Type 1 (including Type 1C) or Type 2A Von Willebrand Disease confirmed by lab results
  • History of bleeding symptoms with at least 3 bleeding episodes per year requiring treatment or ongoing heavy menstrual bleeding at enrollment
Not Eligible

You will not qualify if you...

  • History of significant allergic reactions to monoclonal antibody therapies
  • Personal history of venous or arterial thrombosis except certain superficial vein thrombosis
  • High-risk thrombophilia conditions such as homozygous Factor V Leiden or congenital protein deficiencies
  • Need for ongoing bleed-prevention treatment
  • Other severe bleeding disorders besides Von Willebrand Disease
  • Planned major surgery during the study period
  • Conditions increasing thrombosis risk including obesity, reduced mobility, active cancer, recent surgery or childbirth
  • Pregnancy or plans to become pregnant within 6 months after consent
  • Significant cardiovascular diseases including heart failure, coronary artery disease, arrhythmias, and stroke
  • Other risk factors increasing cardiovascular event risk like smoking or uncontrolled hypertension
  • Concurrent diseases, treatments, or medications affecting bleeding or study completion
  • Participation in investigational product studies within 30 days prior to screening or recent participation in related Velora Pioneer study

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Diagnostic Evaluation

Duration - Up to 2 weeks

Participants undergo baseline evaluation including confirmation of Von Willebrand Disease type and bleeding history.

1 baseline visit (in-person)

Long-term Monitoring

Duration - Approximately 4 months with optional extension up to 12 months

Participants are observed approximately 4 months with regular telemedicine check-ins to monitor bleeding events and treatments. An optional extension up to 12 months is available for those wishing to continue.

Biweekly telemedicine check-ins

Trial Site Locations

Total: 17 locations

1

Phoenix Children's Hospital

Phoenix, Arizona, United States, 85016

Actively Recruiting

2

Arkansas Children's Hospital

Little Rock, Arkansas, United States, 72202-3591

Actively Recruiting

3

Children's Hospital of Los Angeles

Los Angeles, California, United States, 90027

Actively Recruiting

4

University of Miami Hospital and Clinics, Sylvester Comprehensive Cancer Center

Miami, Florida, United States, 33136

Actively Recruiting

5

Emory Children's Center

Atlanta, Georgia, United States, 30329

Actively Recruiting

6

Innovative Hematology, Inc./Indiana Hemophilia and Thrombosis Center

Indianapolis, Indiana, United States, 46260

Actively Recruiting

7

Tulane University School of Medicine

New Orleans, Louisiana, United States, 70112-2699

Actively Recruiting

8

University of Michigan Hospitals, Department of Hemophilia and Coagulation Disorders

Ann Arbor, Michigan, United States, 48109

Actively Recruiting

9

Mayo Clinic - Rochester

Rochester, Minnesota, United States, 55905

Actively Recruiting

10

Oregon Health & Science University

Portland, Oregon, United States, 97239-3098

Actively Recruiting

11

Hemophilia Center of Western Pennsylvania

Pittsburgh, Pennsylvania, United States, 15213

Actively Recruiting

12

The University of Texas Southwestern Medical Center

Dallas, Texas, United States, 75390

Actively Recruiting

13

Washington Institute For Coagulation (WIC)

Seattle, Washington, United States, 98101

Actively Recruiting

14

Fiona Stanley Hospital

Murdoch, Perth, Australia, WA 6150

Actively Recruiting

15

Royal Prince Alfred Hospital

Camperdown, Sydney, Australia, NSW 2050

Actively Recruiting

16

The Alfred Hospital

Melbourne, Victoria, Australia, VIC 3004

Actively Recruiting

17

Richmond Pharmacology

London, United Kingdom, SE1 1YR

Actively Recruiting

Loading map...

Research Team

C

Clinical Trials (USA; UK)

C

Clinical Trials (Australia)

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

2

Similar Trials

A Phase 1/2 Study to Assess the Safety, Tolerability, Pharma...

Von Willebrand Disease (VWD)

Actively Recruiting

4 locations

A Clinical Study to Evaluate the Safety, Efficacy and Pharma...

Von Willebrand Disease (VWD)

Actively Recruiting

7 locations

A Phase 3, Open-label Study on Efficacy and Safety of Prophy...

Von Willebrand Disease (VWD)

Actively Recruiting

21 locations

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here